CORE-014: COMPARATIVE PATHOLOGY AND MOUSE PHENOTYPING (CPMPSR) PROJECT SUMMARY / ABSTRACT The Comparative Pathology and Mouse Phenotyping Shared Resource (CPMPSR) provides expert, readily available and affordable pathology support to investigators utilizing animal models to study human cancer. The use of animal models in cancer research, particularly inbred and genetically engineered mice, has increased exponentially over the past several years due to technological advances and completion of the sequencing of the human and mouse genomes. Virtually every OSUCCC member utilizing experimental animal models will need at least some of the services provided by the CPMPSR.
The Specific Aims of the CPMPSR are: 1) to provide support for preclinical efficacy and toxicity studies utilizing a variety of animal species; 2) to provide consultative services to OSUCCC investigators for optimal experimental design, sample submission and data analysis, recommendations as needed for various ancillary tests, referrals to other OSUCCC shared resources and cores, and referrals to investigators' laboratories with specific expertise (e.g., more specialized clinical pathology testing, electron microscopy, imaging, behavioral and physiological testing); and, 3) to provide consultations to investigators at the time of grant applications and manuscript submissions by providing details about methods and pathologic findings. The services provided by CPMPSR, directed by Dr. Krista La Perle include macroscopic and microscopic tissue evaluations, clinical pathology testing, comprehensive histology and immunohistochemistry, microscopic slide imaging and quantitative analysis. The CPMPSR also provides comprehensive phenotypic characterization of genetically-engineered mice, including detailed characterization of embryos. Radiography is performed by the CPMPSR to enhance morphologic evaluations on post-mortem specimens. The CPMPSR regularly interacts with other OSUCCC shared resources such as the Microscopy Shared Resource and Biomedical Informatics Shared Resource. Over the past grant period, the CPMPSR was utilized by all five OSUCCC Research Programs studying carcinogenesis and using preclinical models for drug development. CPMPSR provided services to 117 OSUCCC members, and these members accounted for 53% of usage. The CPMPSR has also supported the research for 93 cancer publications, of which 11 were published in journals with an impact factor >10. The CPMPSR supported 9 programmatic grants (e.g., P01s and SPOREs). The future plans of the CPMPSR are to add capacity through the hiring of an additional pathologist, providing additional immunohistochemistry services and upgrading existing software. The CPMPSR leverages extensive institutional support, and seeks only 6.5% support from CCSG funds. The Comparative Pathology and Mouse Phenotyping Shared Resource is part of the Diagnostics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-43
Application #
9632728
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Madan, Esha; Parker, Taylor M; Bauer, Matthias R et al. (2018) The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53. J Biol Chem 293:4262-4276

Showing the most recent 10 out of 2602 publications